Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial

IMPORTANCE: Easy-to-administer antiviral treatments may be used to prevent progression from asymptomatic infection to COVID-19 and to reduce viral carriage. OBJECTIVE: Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab antibody combination (REGEN-COV) to prevent progression f...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Meagan P., Forleo-Neto, Eduardo, Sarkar, Neena, Isa, Flonza, Hou, Peijie, Chan, Kuo-Chen, Musser, Bret J., Bar, Katharine J., Barnabas, Ruanne V., Barouch, Dan H., Cohen, Myron S., Hurt, Christopher B., Burwen, Dale R., Marovich, Mary A., Brown, Elizabeth R., Heirman, Ingeborg, Davis, John D., Turner, Kenneth C., Ramesh, Divya, Mahmood, Adnan, Hooper, Andrea T., Hamilton, Jennifer D., Kim, Yunji, Purcell, Lisa A., Baum, Alina, Kyratsous, Christos A., Krainson, James, Perez-Perez, Richard, Mohseni, Rizwana, Kowal, Bari, DiCioccio, A. Thomas, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D., Weinreich, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219113/
https://www.ncbi.nlm.nih.gov/pubmed/34159343
http://dx.doi.org/10.1101/2021.06.14.21258569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219113/
https://www.ncbi.nlm.nih.gov/pubmed/34159343
http://dx.doi.org/10.1101/2021.06.14.21258569

Ejemplares similares